Andrew Bayliffe is the founder of Marengo Therapeutics. Marengo Therapeutics has raised $80M in total funding. Latest round: Series B. Based in Cambridge, MA.
Andrew Bayliffe is the Chief Scientific Officer at Marengo Therapeutics, a clinical-stage biotechnology company. Marengo Therapeutics develops precision immunotherapies using its selective T-cell activation repertoire (STAR) platform to engineer novel TCR-targeting antibodies.
Full founder directory · Investor directory · Company funding database · Fundraising library